[Solid tumors after kidney transplantation].

Area of Science:

• Nephrology
• Oncology
• Immunology

Background:

• Kidney transplant patients exhibit a 3-5 times higher overall cancer risk compared to the general population.
• Cutaneous epitheliomas are the most frequent post-transplant malignancy, with a 100-fold increased risk.
• Cancer development is multifactorial, including impaired immunosurveillance, viral infections, genetic factors, and immunosuppressive drugs like azathioprine and anticalcineurins.

Purpose of the Study:

• To highlight the increased cancer risk in kidney transplant recipients.
• To outline essential monitoring and prevention strategies before and after transplantation.
• To discuss the role of proliferation signal inhibitors in managing cancer in transplant patients.

Main Methods:

• Review of existing literature on post-transplantation cancer.
• Analysis of risk factors associated with immunosuppressive therapies.
• Evaluation of management strategies for cancer in kidney transplant recipients.

Main Results:

• Specific immunosuppressors (azathioprine, anticalcineurins) are linked to elevated cancer risk.
• Proactive screening and risk factor modification pre-transplant are crucial.
• Post-transplant surveillance, sun protection, and tailored immunosuppression are vital for prevention.
• Proliferation signal inhibitors offer a means to maintain immunosuppression while combating cancer, preserving the graft.

Conclusions:

• Kidney transplant recipients require rigorous, lifelong cancer surveillance.
• Early detection and management, including the use of specific immunosuppressive agents, can improve cancer survival rates without compromising graft function.
• Personalized immunosuppression strategies are key to balancing cancer risk and graft survival.